Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 5/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.41 |
| ▸ | BACE1 | P56817 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.40 |
| ▸ | HTR1A | P08908 | 1/20 | 0.40 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.40 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.40 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.40 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.40 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.40 |
| ▸ | DRD1 | P21728 | 1/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.40 |
| ▸ | HTR2A | P28223 | 1/20 | 0.40 |
| ▸ | HTR2C | P28335 | 1/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.40 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.40 |
| ▸ | HRH1 | P35367 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8022326 | 0.78 | DRD2 (0.43) | DRD2TRPA1BACE1LMNACHRM2 | |
| SCHEMBL22328965 | 0.78 | MAPT (0.39) | DRD2KDM4EALDH1A1BACE1LMNA | |
| SCHEMBL8470 | 0.76 | DRD2 (0.47) | DRD2TRPA1BACE1LMNACHRM2 | |
| SCHEMBL20829220 | 0.76 | DRD2 (0.47) | DRD2ALDH1A1TRPA1BACE1LMNA | |
| SCHEMBL88348 | 0.76 | BACE1 (0.57) | DRD2KDM4ETRPA1BACE1LMNA | |
| SCHEMBL12778506 | 0.76 | DRD2 (0.47) | DRD2ALDH1A1TRPA1BACE1LMNA | |
| SCHEMBL12844946 | 0.76 | DRD2 (0.47) | DRD2ALDH1A1TRPA1BACE1LMNA | |
| SCHEMBL22328980 | 0.76 | MAPT (0.39) | DRD2KDM4EALDH1A1LMNACHRM2 | |
| SCHEMBL10202613 | 0.76 | DRD2 (0.44) | DRD2TRPA1BACE1LMNACHRM2 | |
| SCHEMBL12045010 | 0.76 | DRD2 (0.44) | DRD2ALDH1A1TRPA1BACE1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4124616-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHOLOGICAL DISORDERS | Alkermes Pharma Ireland Limited (IE) | 2023-02-01 | — | — | EP | disclosed |
| EP-2445343-B1 | PRODRUGS OF NH-ACIDIC COMPOUNDS | ALKERMES PHARMA IRELAND LTD (IE) | 2021-08-04 | — | — | EP | disclosed |
| EP-3305784-B1 | HAPTENS OF QUETIAPINE FOR USE IN IMMUNOASSAYS | JANSSEN PHARMACEUTICA NV (BE) | 2020-08-12 | — | — | EP | disclosed |
| EP-3686201-A1 | INFLUENZA VIRUS REPLICATION INHIBITOR AND USE THEREOF | Sunshine Lake Pharma Co., Ltd. (CN) | 2020-07-29 | — | — | EP | disclosed |
| EP-3309151-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHOLOGICAL DISORDERS | Alkermes Pharma Ireland Limited (IE) | 2018-04-18 | — | — | EP | disclosed |
| US-20170000749-A1 | Methods for Treating Cognitive Disorders Using Inhibitors of Histone Deacetylase | FMR LLC | 2017-01-05 | — | — | US | disclosed |
| US-20160222026-A1 | Dibenzo[B,F][1,4]oxazepin-11-yl-N-Hydroxybenzamides as HDAC Inhibitors | FMR LLC | 2016-08-04 | — | — | US | disclosed |
| US-9156820-B2 | Polycyclic heteroaryl substituted triazoles useful as axl inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2015-10-13 | — | — | US | disclosed |
| US-20140323490-A1 | POLYCYCLIC HETEROARYL SUBSTITUTED TRIAZOLES USEFUL AS AXL INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2014-10-30 | — | — | US | disclosed |
| US-8741898-B2 | Polycyclic heteroaryl substituted triazoles useful as Axl inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2014-06-03 | — | — | US | disclosed |
| US-20110092483-A1 | SCREENING MOLECULES WITH ANTI-PRION ACTIVITY: KITS, METHODS AND SCREENED MOLECULES | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2011-04-21 | — | — | US | disclosed |
| US-7902355-B2 | Condensation of 10H-dibenzo-[b,f][1,4]-thiazepin-11-one with a piperazine derivative in the presence of a titanium alkoxide catalyst; Titanium catalyst easier to handle, have low toxicity, not chlorinated, much less harmful for the environment | UNION QUIMICO-FARMACEUTICA S.A. (ES) | 2011-03-08 | — | — | US | disclosed |
| US-7902355-B2 | Condensation of 10H-dibenzo-[b,f][1,4]-thiazepin-11-one with a piperazine derivative in the presence of a titanium alkoxide catalyst; Titanium catalyst easier to handle, have low toxicity, not chlorinated, much less harmful for the environment | UNION QUIMICO-FARMACEUTICA S.A. (ES) | 2011-03-08 | — | — | US | disclosed |
| EP-1856073-B1 | A PROCESS FOR THE PREPARATION OF AN 11-(4-SUBSTITUTED-I-PIPERAZINYL)DIBENZO[b,f][1,4]THIAZEPINE DERIVATIVE | UNION QUIMICO FARMA (ES) | 2010-05-12 | — | — | EP | disclosed |
| WO-2008121415-A2 | IMPROVED PROCESS FOR PREPARING QUETIAPINE FUMARATE | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2008-10-09 | — | — | WO | disclosed |
| US-20080171869-A1 | Process For The Preparation Of An 11-(4-Substituted-I- Piperazinyl)Dibenzo[B,F][1,4:rsqb; Thiazepine Derivative | UNION QUIMICO-FARMACEUTICA S.A. (ES) | 2008-07-17 | — | — | US | disclosed |
| US-20080171869-A1 | Process For The Preparation Of An 11-(4-Substituted-I- Piperazinyl)Dibenzo[B,F][1,4:rsqb; Thiazepine Derivative | UNION QUIMICO-FARMACEUTICA S.A. (ES) | 2008-07-17 | — | — | US | disclosed |
| WO-2008066620-A2 | DIBENZOTHIAZEPINE DERIVATIVES | CONCERT PHARMACEUTICALS INC. (US) | 2008-06-05 | — | — | WO | disclosed |
| EP-1602650-B1 | Method for the preparation of quetiapine by reductive N-alkylation of 11-Piperazinodibenzo(B,F) (1,4)Thioazepin with an aldehyde | CELON PHARMA SP Z O O (PL) | 2007-10-24 | — | — | EP | disclosed |
| US-20070031821-A1 | Screening molecules with anti-prion activity: kits, methods and screened molecules | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS ) (FR) | 2007-02-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110092483-A1 | SCREENING MOLECULES WITH ANTI-PRION ACTIVITY: KITS, METHODS AND SCREENED MOLECULES | ATXN2L, ATXN10, CLN6 | DRD2 2733/4885KDM4E 2700/4885ALDH1A1 2586/4885 |
| US-20140323490-A1 | POLYCYCLIC HETEROARYL SUBSTITUTED TRIAZOLES USEFUL AS AXL INHIBITORS | AXL, TYRO3, ERBB3 | DRD2 4431/4885KDM4E 4036/4885ALDH1A1 4540/4885 |
| US-20170000749-A1 | Methods for Treating Cognitive Disorders Using Inhibitors of Histone Deacetylase | HDAC5, KAT2A, HDAC1 | DRD2 996/4885KDM4E 125/4885ALDH1A1 1086/4885 |
| US-20080171869-A1 | Process For The Preparation Of An 11-(4-Substituted-I- Piperazinyl)Dibenzo[B,F][1,4:rsqb; Thiazepine Derivative | SDHB, SDHA, CYP2F1 | DRD2 907/4885KDM4E 683/4885ALDH1A1 513/4885 |
| US-20070031821-A1 | Screening molecules with anti-prion activity: kits, methods and screened molecules | ATXN2L, ATXN10, CLN6 | DRD2 2733/4885KDM4E 2700/4885ALDH1A1 2586/4885 |
| US-20160222026-A1 | Dibenzo[B,F][1,4]oxazepin-11-yl-N-Hydroxybenzamides as HDAC Inhibitors | HDAC1, HDAC2, HDAC4 | DRD2 947/4885KDM4E 52/4885ALDH1A1 235/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.